Paget disease is commonly asymptomatic and discovered when an imaging test is performed for another clinical indication or when elevated serum alkaline phosphatase is found. Bone pain usually appears late in the disease process and is only present in a minority of patients. For diagnosis, X-ray and bone scan are the most recommended imaging methods; radionuclide imaging of the skeleton has become the standard, since it is the most sensitive test for detecting increased bone activity. For treatment, either bisphosphonates or calcitonin are recommended.
We present a 74-year-old patient diagnosed with prostate cancer in 2001 who developed bone metastases concomitant with a Paget bone disease.
This patient received treatment with Ra-223, having stable disease in bone scan and no relevant toxicities.
There is no clinical experience with Ra-223 and Paget disease, since it is characterized classically as a high bone turnover disease and therefore there is no rationale to administer a drug that has a high bone affinity. Nevertheless, Ra-223 is not contraindicated.
Tumori 2017; 103(Suppl. 1): e53 - e55
Article Type: CASE REPORT
AuthorsLina García Cañamaque, Cristina Rioja Parada, Paloma García De la Peña
- • Accepted on 24/04/2017
- • Available online on 18/05/2017
- • Published online on 15/11/2017
This article is available as full text PDF.
- García Cañamaque, Lina [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
- Rioja Parada, Cristina [PubMed] [Google Scholar] 1
- García De la Peña, Paloma [PubMed] [Google Scholar] 2
Department of Nuclear Medicine, Centro Integral Oncológico Clara Campal (CIOCC), Hospital de Madrid Sanchinarro, Grupo HM Hospitales, Madrid - Spain
Departament of Rheumatology, Centro Integral Oncológico Clara Campal (CIOCC), Hospital de Madrid Sanchinarro, Grupo HM Hospitales, Madrid - Spain